Sandoz stock costs EUR 88.85 ahead of October 28 sales update

Published on 10/27/2026 at 10:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ahead of October 28, Sandoz stock costs EUR 88.85 on October 27, 2026. First-half sales rose 5.00 percent and biosimilars grew 20.00 percent.

Growth and reporting date

Sandoz delivered 5.00 percent first-half sales growth on August 5, 2026.
Biosimilar sales increased 20.00 percent in the first half of 2026.
Sandoz stock traded at EUR 88.85 at 10:31 a.m. CEST at Lang & Schwarz on October 27, 2026.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz stock (ISIN CH1243598427) costs EUR 88.85 at Lang & Schwarz on October 27, 2026, at 10:31 a.m. CEST. The company is due to publish its nine-month and third-quarter 2026 sales update on October 28, according to VZ.

First-half growth sets context

Sandoz entered the reporting date with first-half net sales up 5.00 percent, while biosimilar sales increased 20.00 percent. The figures came from the company's August 5, 2026 earnings call, published by Yahoo Finance.

The same call showed a core EBITDA margin of 20.90 percent in the first half, up 90 basis points year over year. Management also confirmed full-year 2026 guidance for mid-to-high-single-digit constant-currency sales growth and core EBITDA margin expansion of about 100 basis points.

What does the pipeline mean?

Biosimilars represented 33.00 percent of first-half net sales, giving the October update a clear operating test: whether recent launches continued to offset pricing pressure. Sandoz said its biosimilar pipeline contained 36 assets in the first half, while 13 biosimilars were already on the market.

Three dated milestones

On August 5, 2026, Sandoz reported 5.00 percent first-half net sales growth and 20.00 percent biosimilar growth through Yahoo Finance. On September 29, 2026, the company opened a high-volume biosimilar drug-substance center in Slovenia, as listed by MarketScreener. On October 28, 2026, Sandoz is scheduled to release its third-quarter sales update.

Next reporting date

The next substantiated company date is October 28, 2026, for the nine-month and third-quarter sales release. The update will show whether the 20.00 percent first-half biosimilar growth rate carried into the third quarter.

Stock and investor context

Analyst attention has also shifted ahead of the release. Oddo BHF kept a Neutral rating and raised its target from CHF 62.00 to CHF 75.00 on October 20, 2026, according to Zonebourse. The Swiss-listed company is part of the SMI, and its core question is whether volume growth can continue to absorb price erosion.

Quote before the sales update

Sandoz stock was trading at EUR 88.85 at Lang & Schwarz on October 27, 2026, at 10:31 a.m. CEST. The company reports its next sales figures on October 28, 2026. The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.